Vienna Brunt
Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hyperthermia, Induced | 5 | 2021 | 65 | 2.530 |
Why?
| Vasodilation | 14 | 2022 | 419 | 2.440 |
Why?
| Hot Temperature | 12 | 2021 | 302 | 2.310 |
Why?
| Methylamines | 5 | 2022 | 30 | 1.960 |
Why?
| Vascular Stiffness | 6 | 2022 | 407 | 1.960 |
Why?
| Aging | 10 | 2023 | 1618 | 1.910 |
Why?
| Skin | 9 | 2017 | 655 | 1.650 |
Why?
| Endothelium, Vascular | 7 | 2022 | 843 | 1.540 |
Why?
| Vascular Diseases | 3 | 2023 | 230 | 1.520 |
Why?
| Drinking Water | 2 | 2022 | 64 | 1.510 |
Why?
| Nitric Oxide | 9 | 2023 | 823 | 1.310 |
Why?
| Microcirculation | 4 | 2017 | 135 | 1.060 |
Why?
| Oxidative Stress | 3 | 2021 | 1076 | 1.000 |
Why?
| Potassium Channels, Calcium-Activated | 3 | 2016 | 9 | 0.990 |
Why?
| Hyperemia | 4 | 2014 | 45 | 0.980 |
Why?
| Gastrointestinal Microbiome | 3 | 2020 | 501 | 0.980 |
Why?
| Brachial Artery | 5 | 2021 | 176 | 0.980 |
Why?
| Acetylcholine | 5 | 2022 | 166 | 0.980 |
Why?
| Carotid Arteries | 5 | 2021 | 180 | 0.860 |
Why?
| Cardiovascular Diseases | 4 | 2022 | 1727 | 0.850 |
Why?
| Blood Pressure | 6 | 2021 | 1538 | 0.840 |
Why?
| Lyases | 1 | 2022 | 9 | 0.820 |
Why?
| Progesterone | 3 | 2013 | 232 | 0.820 |
Why?
| Aorta | 3 | 2021 | 386 | 0.810 |
Why?
| Femoral Artery | 2 | 2020 | 167 | 0.760 |
Why?
| Steam Bath | 1 | 2021 | 1 | 0.760 |
Why?
| Hydrotherapy | 1 | 2021 | 8 | 0.750 |
Why?
| Immersion | 2 | 2021 | 5 | 0.750 |
Why?
| Skin Physiological Phenomena | 4 | 2017 | 26 | 0.730 |
Why?
| Estradiol | 3 | 2013 | 455 | 0.730 |
Why?
| Cardiovascular System | 2 | 2021 | 125 | 0.700 |
Why?
| Blood Flow Velocity | 5 | 2021 | 387 | 0.700 |
Why?
| Frailty | 1 | 2022 | 115 | 0.680 |
Why?
| Satellite Cells, Skeletal Muscle | 1 | 2020 | 24 | 0.670 |
Why?
| Pulse Wave Analysis | 5 | 2023 | 207 | 0.660 |
Why?
| Sarcopenia | 1 | 2020 | 63 | 0.620 |
Why?
| Myocardial Ischemia | 1 | 2018 | 235 | 0.550 |
Why?
| Vasodilator Agents | 4 | 2017 | 302 | 0.520 |
Why?
| Acclimatization | 1 | 2017 | 149 | 0.510 |
Why?
| Biological Factors | 2 | 2013 | 35 | 0.510 |
Why?
| Young Adult | 14 | 2021 | 10455 | 0.490 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2022 | 1879 | 0.480 |
Why?
| Skin Temperature | 2 | 2012 | 16 | 0.480 |
Why?
| Peripheral Arterial Disease | 1 | 2020 | 380 | 0.470 |
Why?
| Reperfusion Injury | 1 | 2016 | 255 | 0.460 |
Why?
| Hemodynamics | 2 | 2021 | 1012 | 0.450 |
Why?
| Heart | 2 | 2018 | 612 | 0.450 |
Why?
| Mice | 11 | 2023 | 14860 | 0.440 |
Why?
| Mice, Inbred C57BL | 6 | 2023 | 4689 | 0.440 |
Why?
| Pressoreceptors | 1 | 2013 | 18 | 0.430 |
Why?
| Vasomotor System | 1 | 2013 | 39 | 0.430 |
Why?
| Baroreflex | 1 | 2013 | 54 | 0.420 |
Why?
| Eicosanoids | 1 | 2012 | 54 | 0.400 |
Why?
| Xanthine Oxidase | 1 | 2011 | 71 | 0.370 |
Why?
| Progestins | 1 | 2011 | 75 | 0.360 |
Why?
| NADPH Oxidases | 1 | 2011 | 120 | 0.360 |
Why?
| Angiotensin II | 1 | 2011 | 86 | 0.360 |
Why?
| Superoxides | 2 | 2022 | 214 | 0.360 |
Why?
| Animals | 13 | 2023 | 31694 | 0.360 |
Why?
| Reactive Oxygen Species | 2 | 2021 | 531 | 0.350 |
Why?
| Anti-Bacterial Agents | 1 | 2019 | 1477 | 0.340 |
Why?
| Humans | 29 | 2023 | 114623 | 0.330 |
Why?
| Heating | 3 | 2017 | 17 | 0.310 |
Why?
| Estrogens | 1 | 2011 | 312 | 0.310 |
Why?
| Inflammation | 4 | 2023 | 2477 | 0.300 |
Why?
| Cyclic N-Oxides | 2 | 2020 | 30 | 0.290 |
Why?
| Male | 18 | 2021 | 55554 | 0.280 |
Why?
| Interleukin-1 | 2 | 2022 | 966 | 0.270 |
Why?
| NG-Nitroarginine Methyl Ester | 4 | 2014 | 38 | 0.270 |
Why?
| Forearm | 2 | 2017 | 112 | 0.270 |
Why?
| Female | 18 | 2021 | 59466 | 0.260 |
Why?
| Cellular Senescence | 2 | 2023 | 152 | 0.250 |
Why?
| Arteries | 2 | 2023 | 247 | 0.240 |
Why?
| Glucose | 2 | 2020 | 896 | 0.240 |
Why?
| Endothelial Cells | 2 | 2020 | 681 | 0.240 |
Why?
| Adult | 12 | 2021 | 30528 | 0.230 |
Why?
| Flavonols | 1 | 2023 | 11 | 0.230 |
Why?
| Antioxidants | 2 | 2020 | 530 | 0.220 |
Why?
| Regional Blood Flow | 5 | 2021 | 424 | 0.220 |
Why?
| Tetraethylammonium | 2 | 2013 | 15 | 0.210 |
Why?
| Butanols | 1 | 2022 | 8 | 0.210 |
Why?
| Heart Rate | 2 | 2018 | 709 | 0.200 |
Why?
| Spin Labels | 2 | 2020 | 44 | 0.200 |
Why?
| Sugars | 1 | 2022 | 29 | 0.200 |
Why?
| Nitric Oxide Synthase | 2 | 2013 | 209 | 0.200 |
Why?
| Diet, Western | 1 | 2022 | 66 | 0.200 |
Why?
| Ultrasonography, Doppler | 3 | 2021 | 105 | 0.200 |
Why?
| Carotid Artery, Common | 1 | 2021 | 29 | 0.190 |
Why?
| Spirostans | 1 | 2021 | 4 | 0.190 |
Why?
| Middle Aged | 5 | 2022 | 26719 | 0.180 |
Why?
| Age Factors | 2 | 2021 | 2894 | 0.180 |
Why?
| Dietary Supplements | 2 | 2023 | 460 | 0.180 |
Why?
| Interleukins | 1 | 2022 | 236 | 0.180 |
Why?
| Reflex | 1 | 2020 | 64 | 0.170 |
Why?
| C-Reactive Protein | 1 | 2022 | 362 | 0.170 |
Why?
| Aged | 4 | 2022 | 19061 | 0.170 |
Why?
| Doxorubicin | 1 | 2021 | 285 | 0.170 |
Why?
| Ascorbic Acid | 1 | 2020 | 110 | 0.170 |
Why?
| Microdialysis | 3 | 2014 | 49 | 0.170 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2020 | 184 | 0.170 |
Why?
| Tyrosine | 1 | 2020 | 214 | 0.170 |
Why?
| Prostaglandin-Endoperoxide Synthases | 2 | 2016 | 58 | 0.160 |
Why?
| Heme Oxygenase-1 | 1 | 2018 | 52 | 0.150 |
Why?
| Exercise Tolerance | 1 | 2019 | 213 | 0.150 |
Why?
| Transcription Factor RelA | 1 | 2018 | 82 | 0.150 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2018 | 89 | 0.150 |
Why?
| Adolescent | 5 | 2021 | 17831 | 0.150 |
Why?
| Muscle Contraction | 1 | 2020 | 389 | 0.140 |
Why?
| Extracellular Matrix | 1 | 2021 | 436 | 0.140 |
Why?
| Polycystic Ovary Syndrome | 1 | 2019 | 141 | 0.140 |
Why?
| Arterial Pressure | 2 | 2017 | 99 | 0.140 |
Why?
| Laser-Doppler Flowmetry | 2 | 2013 | 32 | 0.140 |
Why?
| Shear Strength | 1 | 2016 | 65 | 0.140 |
Why?
| Heat-Shock Response | 1 | 2016 | 46 | 0.130 |
Why?
| Smoking | 2 | 2014 | 1380 | 0.130 |
Why?
| Carotid Intima-Media Thickness | 1 | 2016 | 65 | 0.130 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2021 | 1139 | 0.130 |
Why?
| Vascular Resistance | 1 | 2016 | 337 | 0.120 |
Why?
| Time Factors | 3 | 2021 | 6112 | 0.120 |
Why?
| Healthy Volunteers | 1 | 2015 | 197 | 0.120 |
Why?
| Interleukin-6 | 1 | 2018 | 676 | 0.120 |
Why?
| Stroke Volume | 1 | 2017 | 504 | 0.120 |
Why?
| Microvessels | 1 | 2014 | 68 | 0.110 |
Why?
| Transdermal Patch | 1 | 2013 | 15 | 0.110 |
Why?
| Adaptation, Physiological | 1 | 2017 | 483 | 0.110 |
Why?
| Hormone Antagonists | 1 | 2013 | 33 | 0.110 |
Why?
| Sex Factors | 2 | 2021 | 1715 | 0.110 |
Why?
| Cognition | 1 | 2020 | 988 | 0.110 |
Why?
| Administration, Cutaneous | 1 | 2013 | 117 | 0.110 |
Why?
| Prostaglandins | 1 | 2013 | 77 | 0.100 |
Why?
| Cell Differentiation | 1 | 2020 | 1700 | 0.100 |
Why?
| Sulfaphenazole | 1 | 2012 | 3 | 0.100 |
Why?
| Cytochrome P-450 CYP2C9 | 1 | 2012 | 17 | 0.100 |
Why?
| Potassium Channel Blockers | 1 | 2012 | 29 | 0.100 |
Why?
| Enzyme Inhibitors | 2 | 2013 | 750 | 0.100 |
Why?
| Rats | 1 | 2020 | 4958 | 0.100 |
Why?
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 41 | 0.100 |
Why?
| Gonadotropin-Releasing Hormone | 1 | 2013 | 188 | 0.100 |
Why?
| Estrogen Antagonists | 1 | 2011 | 39 | 0.100 |
Why?
| Drug Administration Schedule | 1 | 2013 | 718 | 0.090 |
Why?
| Administration, Oral | 1 | 2013 | 728 | 0.090 |
Why?
| Linear Models | 1 | 2013 | 768 | 0.090 |
Why?
| Cells, Cultured | 1 | 2018 | 3881 | 0.090 |
Why?
| Analysis of Variance | 1 | 2013 | 1226 | 0.090 |
Why?
| Antineoplastic Agents | 1 | 2021 | 1879 | 0.090 |
Why?
| Obesity | 1 | 2019 | 2507 | 0.070 |
Why?
| Treatment Outcome | 2 | 2016 | 9084 | 0.060 |
Why?
| Elastin | 1 | 2021 | 78 | 0.050 |
Why?
| Collagen | 1 | 2021 | 415 | 0.040 |
Why?
| Sympathetic Nervous System | 1 | 2019 | 171 | 0.040 |
Why?
| Congresses as Topic | 1 | 2018 | 195 | 0.030 |
Why?
| Ventricular Dysfunction, Left | 1 | 2017 | 358 | 0.030 |
Why?
| Skin Aging | 1 | 2013 | 19 | 0.030 |
Why?
| Ketorolac | 1 | 2013 | 16 | 0.030 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2013 | 72 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2016 | 1842 | 0.020 |
Why?
| Electrocardiography | 1 | 2011 | 560 | 0.020 |
Why?
| Exercise | 1 | 2017 | 1644 | 0.020 |
Why?
| Risk Factors | 1 | 2019 | 8628 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2011 | 4411 | 0.010 |
Why?
|
|
Brunt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|